29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, We read with interest the article by Taneja et al.[1] We believe that it was a great effort considering the number of studies on this particular group and no such study in our population group. There is relatively low awareness about these ophthalmic manifestations of thalassemia and this article would go a long way to create awareness about the same. We want to share our own experience (presented as a free paper in AIOC 2009, Jaipur) which is different from their findings, especially in the untreated and treated group with desferioxamine. A total of 112 children (224 eyes) with beta thalassemia were taken for the study. Ninety-five children (190 eyes, 84.8%) not on desferioxamine therapy were termed as case group and 17 children (34 eyes, 15.2%) were on desferioxamine and called control group. Out of 95 children, 62 (65.2%) were male. All children were under the age of 15 years (4-15 years) who had received multiple blood transfusions. Conjunctival blanching and isolated cataractous changes in the lens were the most common anterior segment findings in the untreated group. Both were found in 12 (6.3%) eyes. The rest of the findings are listed in Table 1. In the group on desferioxamine, none of these children had any opacity in the lens. Four (11.8%) had tessellated fundus in the control group. Table 1 Various ocular manifestations in the untreated group Anterior segment findings No. of eyes (%) Posterior segment findings No. of eyes (%) Conjunctival Blanching 12 (6.3) Tessellated fundus 55 (28.9) Lens opacities 12 (6.3) Temporal pallor 8 (4.2) Xerosis/ Bitot’s spot 8 (4.2) Area of pigmentation 6 (3.1) Heterochromia 4 (2.1) Albinotic fundus 4 (2.1) Pseduophakia 2 (1) Nevus 2 (1) Abduction deficit (lateral rectus underaction) 2 (1) Venous dilatation 2 (1) Telecanthus 2 (1) Nasal tilting 1 (0.5) Persistent 1 (0.5) Snow flake degeneration 1 (0.5) Pupillary membrane Area of depigmentation 1 (0.5) Sheathing 1 (0.5) The ocular manifestations were compared in the untreated group with respect to serum ferritin [Table 2]. We compared our data with other studies and found lens opacities were commoner in our study (14 eyes 7.3%). Table 2 The distribution of various ocular manifestation visa-vis ferritin levels Serum ferritin Less than 500 501-999 1000-4999 5000 and above Anterior segment findings No. of affected eyes (%) Conjunctival Blanching 12 (6.3) Lens opacities 2 (1) 10 (5) Conjunctival Blanching 12 (6.3) Xerosis/ Bitot’s spot 8 (4.2) Heterochromia Telecanthus 4 (2.1) Posterior segment findings No. of affected eyes (%) Tessellated fundus 3 (1.6) Temporal pallor 2 (1) Area of pigmentation Albinotic fundus 1 (0.5) 1 (0.5) 3 (1.6) 2 (1) Nevus 1 (0.5) 1 (0.5) Venous dilatation 1 (0.5) Goldberg et al.[2] did not find a single case with lens opacity. However, his patients were mainly with sickle cell hemoglobinopathy and not beta thalassemia patients. Degeneration of retinal pigment epithelium (RPE) and tessellated fundus were common in our study as has been noted in a previous study by Gartaganis et al.[3] We could not find a single case with angioid streaks even when our case series was larger. We saw untreated cases and therefore, could see that the effects on the eye were mainly because of the iron overload and not secondary to chelating therapy as has been thought. We could not find a single case of lens opacities in children (small sample size) with reduced serum ferritin levels. All these children were on chelating therapy. Ocular manifestation in control group was significantly lower and it was comparable to other studies. This suggests that serum ferritin levels and iron load may not be actually responsible for the ocular manifestations of beta thatlessemia. Our study absolves desferioxamine of any role in causing ocular surface disorders. Rather, it is the disease itself which may be responsible for any such disorder. Desferioxamine may be considered safe so far as the eye is concerned. However, since our sample size was small, such results should be interpreted with caution.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population

          Purpose: To study the ocular manifestations in multiple transfused beta-thalassemia major patients and assess the ocular side-effects of iron chelating agents. Materials and Methods: In this prospective observational study, 45 multiple transfused beta-thalassemia major children between six months and 21 years of age were enrolled and assigned groups according to the treatment regimens suggested. Group A received only blood transfusions, Group B blood transfusions with subcutaneous desferrioxamine, Group C blood transfusions with desferrioxamine and oral deferriprone and Group D blood transfusions with deferriprone. Ocular status at the time of enrolment was documented. Subjects were observed quarterly for one year for changes in ocular status arising due to the disease process and due to iron chelation therapy. Children with hemoglobinopathies other than beta-thalassemia major, congenital ocular anomalies and anemia due to other causes were excluded. Results: Ocular involvement was observed in 58% of patients. Lenticular opacities were the most common ocular finding (44%), followed by decreased visual acuity (33%). An increased occurrence of ocular changes was observed with increase of serum ferritin and serum iron levels as well as with higher number of blood transfusions received. Desferrioxamine seemed to have a protective influence on retinal pigment epithelium (RPE) mottling. Occurrence of lenticular opacities and RPE degeneration correlated positively with use of desferrioxamine and deferriprone respectively. Follow-up of patients for one year did not reveal any change in ocular status. Conclusion: Regular ocular examinations can aid in preventing, delaying or ameliorating the ocular complications of thalassemia.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ocular abnormalities in patients with beta thalassemia.

            We examined 29 patients with homozygous beta thalassemia. The mean age of the patients was 15.6 +/- 8.9 years. Twelve patients (mean age, 02.0 +/- 10.4 years) had one or more ocular abnormalities. Five patients had degeneration of the retinal pigment epithelium, one had lens opacities, two had lens opacities and degeneration of the retinal pigment epithelium, one had vascular abnormalities and degeneration of the retinal pigment epithelium, one had angioid streaks, lens opacities, and degeneration of the retinal pigment epithelium, and two had angioid streaks and degeneration of the retinal pigment epithelium. These abnormalities were observed in patients with both forms of beta thalassemia, major and intermedia. The frequency of the ocular abnormalities increased with age. The youngest patient with an ocular abnormality was 6 1/2 years old. There was no correlation between the abnormalities observed and the serum ferritin level, the mean hematocrit value, and the dose of deferoxamine given to the patients.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Ophthalmologic manifestations of sickle cell thalassemia.

                Bookmark

                Author and article information

                Journal
                Indian J Ophthalmol
                IJO
                Indian Journal of Ophthalmology
                Medknow Publications (India )
                0301-4738
                1998-3689
                Sep-Oct 2010
                : 58
                : 5
                : 451-452
                Affiliations
                Dr. Thakorbhai V Patel Eye Institute, Vadodara, India
                [1 ]M & J Western Regional Institute of Ophthalmology, Ahmedabad, India
                [2 ]Department of Pediatrics, BJ Medical College, Ahmedabad, India
                Author notes
                Correspondence to: Dr. Jitendra Jethani, Pediatric Ophthalmology and Strabismus, Dr. Thakorbhai V Patel Eye Institute, Haribhakti Complex, Salatwada, Vadodara, India. E-mail: xethani@ 123456rediffmail.com
                Article
                IJO-58-451
                10.4103/0301-4738.67061
                2992939
                20689215
                5bf5f2a4-47ad-4e18-9efd-b8db38ff94e6
                © Indian Journal of Ophthalmology

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                Letters to Editor

                Ophthalmology & Optometry
                Ophthalmology & Optometry

                Comments

                Comment on this article